A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults.

Trial Profile

A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2012

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novavax
  • Most Recent Events

    • 21 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Results reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICCAC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top